SCM
MRNS

Stonepine Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Stonepine Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-242,327
Closed -$1.17M – 25
2022
Q2 		$1.17M Buy
242,327
+185,580
+327% +$1.13M 0.55% 21
2022
Q1 		$531K Buy
+56,747
New +$564K 0.22% 27

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Stonepine Capital Management's MRNS Position: Q3 2022 in Review

Stonepine Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2022, closing a stake of 242,327 shares — an estimated $1.17M sold.

Stonepine Capital Management first reported a position in MRNS in Q1 2022 and held it in 2 quarters. The position peaked at $1.17M in Q2 2022. 69 funds tracked by Wall St. Rank hold MRNS as of Q3 2022.

  • Stonepine Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2022 after selling out during the quarter.
  • Stonepine Capital Management sold 242,327 Marinus Pharmaceuticals, Inc shares in Q3 2022, an estimated $1.17M.
  • Stonepine Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q1 2022 and held it in 2 quarters.
  • Stonepine Capital Management's Marinus Pharmaceuticals, Inc position peaked at $1.17M in Q2 2022.
  • 69 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2022.

Based on Stonepine Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.